Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review

Eric W Schneider
Mark W Johnson
Department of Ophthalmology and Visual Sciences, University of Michigan, WK Kellogg Eye Center, Ann Arbor, MI, USA

Abstract: With the dissemination of optical coherence tomography over the past two decades, the role of persistent vitreomacular adhesion (VMA) in the development of numerous macular pathologies – including idiopathic macular hole, vitreomacular traction syndrome, cystoid and diabetic macular edema, neovascularization in diabetic retinopathy and retinal vein occlusion, exudative age-related macular degeneration, and myopic traction maculopathy – has been established. While invasive vitreoretinal procedures have long been utilized to address complications related to these disorders, such an approach is hampered by incomplete vitreoretinal separation and vitreous removal, surgical complications, and high costs. In light of such limitations, investigators have increasingly looked to nonsurgical means for the treatment of persistent pathologic VMA. Chief among these alternative measures is the intravitreal application of pharmacologic agents for the induction of vitreous liquefaction and/or vitreoretinal separation, an approach termed pharmacologic vitreolysis. This article aims to review the available evidence regarding the use of pharmacologic agents in the treatment of VMA-related pathology. In addition, a discussion of vitreous molecular organization and principles of physiologic posterior vitreous detachment is provided to allow for a consideration of vitreolytic agent mode of action and molecular targets.

Keywords: macular edema, macular hole, microplasmin, pharmacologic vitreolysis, posterior vitreous detachment, vitreomacular traction syndrome

Introduction

Perhaps owing to its fundamentally “invisible” nature, the vitreous has long been an under recognized cause of macular pathology. More recently, the improved characterization of vitreomacular relationships facilitated by the evolution of optical coherence tomography (OCT) has led to an increasing recognition of the role played by the posterior vitreous in such disorders. Numerous investigators have found an increased prevalence of incomplete posterior vitreous detachment – a surrogate marker for persistent vitreomacular adhesion (VMA) – in association with a number of retinal disorders including idiopathic macular hole,1 vitreomacular traction syndrome (VMT),2 cystoid (CME)3 and diabetic macular edema (DME),4 neovascularization in diabetic retinopathy5 and retinal vein occlusion (RVO),6 exudative age-related macular degeneration (ARMD),7 and myopic traction maculopathy.8 The pathologic role of VMA in many of these disorders relates to the transmission of static and dynamic anteroposterior tractional forces to the macular surface. The specific pathologic phenotype produced depends on the size and strength of the adhesion, with more extensive vitreous separations and smaller areas of vitreous adhesion imparting greater tractional force.8,9 The
role of vitreoretinal and/or vitreomacular adhesion (hereafter referred to collectively as VMA) in the development of neovascularization and nontractional macular edema is less well defined. It may be due in part to residual posterior cortical vitreous acting as a barrier to the flux of important intravitreal molecules (specifically oxygen, growth factors, and cytokines) or as a scaffold for the growth of fibrovascular proliferation arising from the retinal surface.

Of note, careful distinction should be made between pathologic (or “symptomatic”) VMA, a categorization that encompasses the pathologic entities described above, and nonpathologic (or “asymptomatic”) VMA in which persistent attachment of the posterior vitreous to the macula does not result in anatomic or functional impairment. This latter form of VMA is frequently noted incidentally on OCT imaging and represents a physiologic stage I posterior vitreous detachment (PVD). Taken in sum, these descriptions can be utilized to generate a mechanistic classification of disorders associated with pathologic VMA, detailed in Figure 1.

With the introduction of pars plana vitrectomy by Machemer et al in 1971, a definitive solution for VMA-related disease became available to vitreoretinal surgeons. While implementation lagged in line with the delay in recognizing the etiologic role played by the posterior vitreous, the past two decades have seen a dramatic upswing in the application of vitrectomy. In many cases, elimination of vitreoretinal traction and complete separation of the posterior hyaloid from the retinal surface with removal of all vitreous gel lead to both anatomic and functional improvement. Though outcomes have improved with advancements in instrumentation and technique, the utility of vitrectomy remains limited by incomplete vitreoretinal separation and vitreous removal, associated complications, and high costs. Clinical and histologic studies have shown that residual cortical vitreous commonly adheres to the inner retinal surface following vitrectomy despite concentrated aspiration and peeling of the posterior hyaloid. Cortical vitreous remnants may organize into a fibrocellular epiretinal membrane with subsequent contraction causing macular pucker. Indeed, patients with pathologic VMA inherently have exaggerated adherence at the vitreoretinal interface, which in turn leads to a more difficult mechanical separation. Attempts to achieve a cleaner cleavage plane, through mechanical peeling of the internal limiting membrane (ILM), may increase the risk of surgical complications, including retinal hemorrhages, retinal breaks, nerve fiber layer (NFL) damage, and paracentral scotomas.

In light of the inherent limitations associated with vitrectomy for the treatment of pathologic VMA, it is unsurprising that, over the past 15 years, investigators have increasingly examined alternative methods for induction of PVD. Though a few investigators have explored mechanical PVD induction with isolated intraocular gas injection and even LASIK (laser-assisted in-situ keratomileusis) suction rings, the bulk of efforts have focused on the use of pharmacologic agents to modify the molecular structure of the vitreous in order to eliminate its role in disease, a technique termed pharmacologic vitreolysis. In general, this involves the induction of vitreoretinal separation and/or liquefaction of vitreous gel either as monotherapy or in conjunction with vitrectomy. This article aims to review the available evidence to date regarding the application of pharmacologic agents in the endeavor of vitreolysis. A summary of vitreous molecular organization and principles of physiologic PVD will provide context for the consideration of vitreolytic agent mode of action and molecular targets. Following a careful analysis of specific indications for pharmacologic vitreolysis, the individual agents will be reviewed with summaries to include postulated mechanism of action, results of past pre-clinical and clinical trials (if available) as well as a discussion of any

![Figure 1 Schematic representation of mechanistic classification of vitreomacular adhesion-related disease.](https://www.dovepress.com/clinical-ophtalmology-2011-5)

Clinical Ophthalmology downloaded from www.dovepress.com by 54.70.40.11 on 08-Dec-2018
For personal use only.
pending investigations. A final section on emerging trends and future directions will conclude the review.

**Vitreous molecular organization and structure**

Pharmacologic vitreolysis is largely an outgrowth of an evolving understanding of the molecular organization, structure, and physiology of the vitreous. This knowledge has allowed for the selection of appropriate agents to target key molecules and structures within the vitreous gel as well as at the vitreoretinal interface.

Consistent with its dual purpose of maintaining media clarity and mitigating possible concussive effects associated with ocular movement or trauma, the vitreous is a transparent viscoelastic extracellular gel matrix (ECM) composed of approximately 99% water. In the gel state, vitreous further maintains media clarity by acting as a barrier to limit cellular invasion and may also act to protect sensitive tissues such as the crystalline lens and trabecular meshwork from oxidative damage via its role in oxygen metabolism. These unique properties are a direct result of the molecular structure of vitreous gel, which consists of two complementary macromolecular structures: a fibrillar component, represented by collagen; and glycosaminoglycans (GAGs), chiefly hyaluronan with a lesser concentration of chondroitin sulfate. Vitreous collagen consists of heterotypic fibrils composed of a combination of collagen type II, type IX, and a hybrid type V/XI.

As the site of adhesion between the posterior cortical vitreous and the ILM, the vitreoretinal interface plays a decisive role in the relationship between physiologic and pathologic VMA. The interface juxtaposes the ILM, a basement membrane secreted by underlying Müller cells, and the posterior hyaloid. Similar to basal membranes elsewhere in the body, the ILM is compromised chiefly of collagen type IV, which imparts a sheet-like conformation, in addition to several ECM proteins, notably laminin, fibronectin, and collagen type XVIII. Despite this expanding knowledge of vitreoretinal interface components, the mechanisms underlying VMA remain poorly understood. Histologic studies have demonstrated that vitreous collagen fibrils are oriented in an anteroposterior manner and, posterior to the vitreous base, run parallel to the ILM. However, at the vitreous base, vitreous collagen fibrils run perpendicular to and pass through the ILM where they insert to form an adhesion, considered unbreakable without proteolysis. This contrasts with the posterior vitreoretinal interface at which collagen fibrils do not insert into the ILM. Instead, VMA posterior to the vitreous base is thought to be fascial in nature and mediated by some form of “extracellular matrix glue” that connects cortical vitreous collagen fibrils with the ILM surface. ILM-associated molecules suggested as potential “glue” components include laminin and fibronectin, which have been demonstrated to have high affinity for collagen, as well as collagen type XVIII, which has been shown to be bound by the opticin molecules coating vitreous collagen fibrils.

**Principles of physiologic PVD**

The process of physiologic, or age-related, PVD is well characterized from a mechanistic standpoint, but remains poorly understood on a molecular level. While the lack of an accurate molecular description has hampered the development of pharmacologic vitreolitics, improved understanding of the physical sequence of uncomplicated PVD has shed significant light on ways in which it may go awry and induce pathologic sequelae. Within the vitreous gel, two related processes, liquefaction (synchysis) and fibrillar collapse (syneresis), act as the primary motive force driving vitreoretinal separation. Liquefaction originates in the premacular cortical vitreous where it has been detected as early as 2 years of age in fixed autopsy specimens.

Focal collections of liquefaction, or liquefied lacunae, subsequently form throughout the vitreous, increasing in number and size during adolescence and adulthood. This process culminates in the coalescence of extensive areas of synchysis, with approximately 70% of autopsy eyes obtained from donors aged 70 years and greater.
demonstrating at least 50% liquefaction of the vitreous body.\textsuperscript{41} As liquefaction progresses, the collagen fibrillar meshwork undergoes collapse. This leads to the aggregation of collagen into parallel bundles that form thick fibers, seen clinically as syneretic debris, which become progressively dense and tortuous with age.\textsuperscript{35,44} In line with the demonstrated positive correlation between the extent of synchysis/syneresis and PVD incidence,\textsuperscript{41,45,46} liquefaction with subsequent collapse appears to drive vitreoretinal separation following attenuation of the adhesion between the cortical vitreous and ILM of the posterior pole. Though previous investigators believed it to be an acute process,\textsuperscript{41,47} more recent studies indicate that PVD occurs over months to years, beginning as a shallow perifoveal vitreoretinal separation that expands gradually until complete PVD is achieved with acute separation of the vitreous from the optic disc margin.\textsuperscript{8,9}

The weakening of the adhesion between the vitreous and the retina stands as a critical factor in the timing and progression of PVD. Multiple studies have demonstrated that the majority of patients less than age 60 have an intact vitreoretinal interface despite the presence of extensive liquefaction.\textsuperscript{41,45} After age 60, however, there is a much stronger correlation between PVD incidence and extent of liquefaction, indicating the presence of some factor that enhances the effect of liquefaction and collapse on PVD induction; this factor is likely a weakened adhesive force between the retina and vitreous.\textsuperscript{41,45} Variations in strength of this force likely determine whether a given PVD is accompanied by pathologic sequelae. In a subset of eyes, age-related PVD progresses normally except where especially firm vitreoretinal adhesions are encountered in the macula, at the optic disc margin, or at focal sites in the retinal periphery. In such eyes, dynamic (saccadic) vitreous traction is exerted upon the retina at the residual adhesion site(s), leading to various complications including macular hole, VMT, tractional DME, vitreopapillary traction syndrome (VPT), vitreous hemorrhage, and retinal tears.\textsuperscript{5,9} Sebag coined the term “anomalous PVD,” to describe the condition in which the extent of gel liquefaction and collapse exceed the attenuation of vitreoretinal adhesion.\textsuperscript{40} This condition results from disorders that cause premature vitreous liquefaction, including hereditary vitreoretinal syndromes, uveitis, vitreous hemorrhage, and high myopia, and increases the risk of PVD-associated morbidity.

To improve upon existing mechanical methods for the treatment of pathologic PVD, controlled induction of vitreous liquefaction and weakening of vitreoretinal adhesion will be necessary. Targeted pharmacologic agents, capable of altering the molecular organization of the vitreous gel and vitreoretinal interface, have the potential to provide such control.\textsuperscript{22} Unfortunately, the development of these agents has been slowed by the lack of accurate molecular descriptions of the processes in question. As mentioned above, the basis of vitreoretinal adhesion remains poorly described. The same is true of the physiologic weakening of vitreoretinal adhesion that accompanies aging. Investigators have proposed several possible age-related changes— including alterations in Müller cell function,\textsuperscript{49} thickening of the ILM,\textsuperscript{40} or the cumulative effects of incident light-generated free radicals\textsuperscript{67}—as a basis for this weakening. Similarly, models of age-related vitreous liquefaction, implicating incident light-generated free radicals\textsuperscript{52–54} or enzymatic degradation of collagen,\textsuperscript{55–57} have been suggested but remain largely unproven.

**Indications for pharmacologic vitreolysis**

From a pathophysiologic perspective, any manifestation of pathologic VMA should benefit from pharmacologic vitreolysis, based on either release of anteroposterior traction (tractional VMA) or removal of premacular vitreous cortex (nontractional VMA). While this may be true in principle, the selection of appropriate indications for pharmacologic vitreolysis requires careful consideration of utilization models and therapeutic goals.

While early interest in pharmacologic vitreolysis focused on its application as an adjunct to vitrectomy and removal of fibrovascular proliferative membranes,\textsuperscript{58–60} investigators quickly realized its potential as a stand-alone therapy.\textsuperscript{61–63} Indeed, clinical applications of pharmacologic vitreolysis can be broadly grouped into two categories based on utilization model: pharmacology-assisted vitrectomy and pharmacologic PVD induction. In the former model, a pharmacologic agent administered preoperatively acts to either induce vitreous liquefaction, allowing for more rapid vitreous removal, or weaken the vitreoretinal adhesion, allowing for greater ease of mechanical PVD induction with a cleaner vitreoretinal separation.\textsuperscript{15,64–67} More rapid vitreous removal translates into shorter surgical times\textsuperscript{15,25,68} and possibly an increased ability to employ smaller gauge instrumentation,\textsuperscript{69,70} which are associated with reduced postoperative recovery times.\textsuperscript{71,72} Weakening of the vitreoretinal adhesion allows mechanical PVD creation without the use of high suction, which reduces the risk of iatrogenic tears\textsuperscript{71,72} and permits the use of smaller gauge instrumentation not capable of achieving such high levels of aspiration.\textsuperscript{69,73,76} Theoretically, it also facilitates cleaner vitreoretinal separation, avoiding cortical vitreous remnants and thereby reducing postoperative complications.
such as macular pucker, proliferative vitreoretinopathy (PVR),\textsuperscript{78,79} and persistence of diabetic retinopathy-related complications.\textsuperscript{80}

When pharmacologic vitreolysis is used as stand-alone therapy, vitreolytic agents can be employed either as a definitive treatment in active VMA-related disease or as a prophylactic measure in conditions in which PVD is associated with an improved prognosis. Examples of the former include early macular holes, VMT, VPT, and tractional DME/CME,\textsuperscript{8,48} while the latter includes conditions such as DME,\textsuperscript{4} proliferative diabetic retinopathy (PDR),\textsuperscript{5,81,82} RVO,\textsuperscript{6,83–85} and ARMD.\textsuperscript{7,86,87} In all cases, the therapeutic effect results from induction of complete pharmacologic PVD. The basis of the prophylactic benefit of PVD in macular edema and neovascularization remains unclear, but likely relates to the barrier and scaffold functions played by posterior cortical vitreous discussed earlier. Of note, stand-alone vitreolytic therapy has also been utilized strictly for its liquefactive properties in conditions such as non-clearing vitreous hemorrhage;\textsuperscript{88,89} however, this indication is outside the scope of this review as it does not pertain to VMA-related disease.

As is the case with most ophthalmologic therapeutic interventions, pharmacologic vitreolysis is indicated in the conditions discussed above based on its potential to improve anatomical and functional outcomes. In addition to this primary therapeutic objective, ancillary goals should also be considered, including: decreased costs, based on shorter surgical times or decreased incidence of progressive disease requiring surgery; and greater access to therapy, based on the simple instrumentation involved and a possible transition to office-based procedures.\textsuperscript{25,68,90} A reduction in surgical cases, due to either a decreased incidence of advanced disease following prophylactic therapy or due to a transition to office-based treatment of VMA-related disease, would have the additional benefit of reducing patient exposure to vitrectomy-related complications – such as endophthalmitis, cataract, and iatrogenic breaks – as well as complications related to anesthesia.

**Vitreolytic agents**

**Overview**

The biochemical properties requisite in any potential vitreolytic agent include the ability to induce vitreous liquefaction (liquefactants), weakening of the vitreoretinal adhesion (interfactants), or both.\textsuperscript{25,90} These molecular alterations may be accomplished through either nonenzymatic, or more commonly, enzymatic means. Based on these characteristics, the available vitreolytic agents – including those previously tested as well as those that remain under development – can be classified as detailed in Table 1.\textsuperscript{25,90}

The following section aims to review the mechanism of action of each agent and summarize the results of relevant pre-clinical and clinical trials.

**Collagenase**

Bacterial collagenase, purified from *Clostridium histolyticum*, is one of the few proteases known to cleave the type II collagen comprising the fibrillar network of the vitreous gel.\textsuperscript{30} In contrast to fibrillar collagen, the resulting proteolyzed fragments are soluble, allowing for spontaneous denaturation and further degradation by nonspecific proteases.\textsuperscript{91} Prolonged intravitreal incubation of escalating doses of bacterial collagenase in rabbits resulted in dose-dependent liquefaction, but was accompanied by ILM damage and disruption of retinal architecture at doses achieving clinically significant degrees of liquefaction.\textsuperscript{92} Using lower doses and shorter incubation periods, subsequent studies in a rabbit model of PVR demonstrated some focal fibrovascular membrane digestion prior to vitrectomy, although histologic and electrophysiologic toxicity was noted at incubation periods greater than 30 minutes.\textsuperscript{58,60} Later human pilot studies of collagenase-assisted vitrectomy resulted in hemorrhages on the surface of the retina as well as evidence of digestion of retinal vasculature on proliferative membranes,\textsuperscript{59,81} which confirmed earlier reports of severe retinal hemorrhages in rabbits.\textsuperscript{93}

**Chondroitinase**

Although substrate specificity varies depending on the bacterial species of origin, chondroitinase catalyzes the depolymerization of various GAGs including chondroitin sulfate, hyaluronan, and dermatan sulfate.\textsuperscript{94} The role of chondroitin sulfate within the vitreous remains unclear. It is generally found in proteoglycan form as either versican, which is linked to hyaluronan, or as collagen IX, which coats the heterotypic

### Table 1: Classification of pharmacologic vitreolytic agents

<table>
<thead>
<tr>
<th>Enzymatic</th>
<th>Interfactants</th>
<th>Liquefactants</th>
<th>Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dispace</td>
<td>Hyaluronidase</td>
<td>Collagenase</td>
<td>Plasmin</td>
</tr>
<tr>
<td>Nattokinase</td>
<td>Microplasmin</td>
<td>tPA + tPA</td>
<td>plasminogen</td>
</tr>
<tr>
<td>Microplasmin</td>
<td>tPA + plasminogen</td>
<td>tPA</td>
<td>plasminogen activator</td>
</tr>
</tbody>
</table>

**Note:** Vitreosolve® (Vitreoretinal Technologies Inc, Irvine, CA).

**Abbreviations:** RGD, arginine-glycine-aspartate; tPA, tissue plasminogen activator.
Hyaluronidase

Hyaluronidase is an endoglycosidase capable of cleaving bulky hyaluronan molecules, in addition to other GAGs such as chondroitin sulfate, into much smaller fragments. The resulting decreased viscosity within the ECM allows for easier passage of material through the ECM. This property has already been exploited clinically to increase the absorption and dispersion of injected drugs such as anesthetics. As hyaluronidase plays a critical role in maintaining the gel-like character of the vitreous, hyaluronidase possesses considerable potential as a liquefactive agent. Hyaluronidase-mediated vitreous liquefaction has been demonstrated both in vitro and in vivo and more recently, in Phase III trials studying its potential in speeding the clearance of vitreous hemorrhage. Additionally, hyaluronidase was shown to significantly improve the extent of vitreous removal during standardized vitrectomy compared with untreated eyes after incubations of 1 or 3 hours. In view of the clear association between age-related PVD and vitreous liquefaction, hyaluronidase would seem a logical agent for pharmacologic induction of PVD. Initial studies examining low dose (1 U) intravitreal hyaluronidase in conjunction with perfluoropropane gas in a rabbit model exhibited only partial PVD following 3-day incubations; this contrasted with eyes receiving either hyaluronidase or gas alone, in which no PVD was detected. Using higher doses (5–20 U) of hyaluronidase alone in a similar rabbit model, two follow-up studies produced very different outcomes: one reported gradual development of PVD at 5–8 weeks in nearly all experimental eyes at the highest doses (10 and 20 U), while a later study reported no PVD in any experimental eye at 3 and 6 months using a similarly high dose (20 U). Although the source of the discrepancy is unclear, the authors of the latter study implicated inadequacy of the light microscopy and clinical examination for PVD determination employed in the former study compared with the EM techniques utilized in their own study. The poor performance of hyaluronidase (20 U) in PVD induction was confirmed by a separate group, again using EM to assess PVD status, though the incubation period in this study was considerably shorter at 1 week. In terms of safety, hyaluronidase was generally well tolerated up to doses of 20 U at incubation periods ranging from 3 to 28 days. Aside from transient vitreous haze noted at nearly all doses and incubation periods, there was no evidence of retinal structural toxicity, as assessed by EM nor functional toxicity, as assessed by ERG. Reported toxicities at higher doses were mixed, with one group demonstrating disruption of retinal cellular anatomy at doses as low as 30 U (bovine hyaluronidase) for 1 week, while the large Phase III trial using doses of 55 and 75 IU (ovine hyaluronidase) reported only an increased rate of transient moderate-severe iritis. Despite impressive liquefactive capacity, hyaluronidase appears limited in terms of PVD induction as it has no demonstrated impact on the vitreoretinal interface. Investigators hypothesized that the induction of PVD by hyaluronidase follows liquefaction of central vitreous, with collapse and subsequent loss of support for cortical vitreous fibers, rendering it susceptible to separation by mechanical forces such as eye movements. In effect, hyaluronidase produces PVD through an increase in vitreoretinal traction and may worsen existing VMA-related pathologies.
Dispase

A neutral protease obtained from *Bacillus polymyxa*, dispase is known to cleave type IV collagen and fibronectin while laminin and other collagen subtypes are left largely unaltered. Given its activity against type IV collagen, a major component of the ILM, and fibronectin, postulated to be a factor in vitreoretinal adhesion, dispase was tabbed as a vitreolytic agent based on its potential to mediate vitreoretinal disinsertion. Interestingly, dispase was initially utilized intravitreally to generate an animal model of PVR without the addition of exogenous cells. This model was based on the ability of dispase to release endogenous cells – such as fibroblasts, macrophages, and glial cells – from their cellular attachments and recruit them into the vitreous. As PVR generation was achieved with prolonged incubations at very low doses (0.01–0.50 U), later studies investigating the utility of dispase in PVD induction used shorter incubation periods (15–120 minutes) at the same or higher doses. In effect, dispase was only evaluated as an agent for enzyme-assisted vitrectomy due to the fact that removal of the enzyme following a specified incubation would be required to avoid PVR development. In the two earliest such studies, dispase achieved significantly higher rates of spontaneous complete PVD in enucleated pig and human eyes as well as pig eyes in vivo at the majority of doses tested following 15 or 120 minutes of incubation. Neither study revealed significant toxicity, excepting transient vitreous haze. In contrast, a similar study of dispase-assisted vitrectomy in rabbits in vivo using greater doses and incubation times failed to show any effect on PVD induction, and enzyme use was associated with retinal and vitreous hemorrhages. Further evidence of dispase-associated toxicity was found in two follow-up studies in an in-vivo rabbit model: in addition to vitreous hemorrhage and cataract formation, histologic exam revealed disruption of ganglion cell and photoreceptor layers, while ERG testing revealed significant depression of a- and b-wave amplitudes. These studies did employ longer incubations (1 week), but clinical evidence of toxicity was noted as early as 30 minutes following injection. The reason for the conflicting results regarding the safety and efficacy of dispase in vitreolysis is unclear but may be related to the model used. Regardless, given its ability to generate PVR as well as its action on collagen IV, a major component of the ILM and lenticular capsule, the safety of dispase remains questionable at best.

Nattokinase

Originally discovered in the Japanese soybean cheese nattō, nattokinase is a serine protease produced by *Bacillus subtilius*. Although incompletely characterized, it is known to possess potent fibrinolytic effects likely due to its enhancement of plasmin activation via increased synthesis of tissue plasminogen activator (tPA) as well as inactivation of plasmin activator inhibitors. Additionally, nattokinase has direct proteolytic effects on collagen. Thus, the postulated PVD induction mechanism of nattokinase involves some combination of direct liquefaction and plasmin-mediated vitreoretinal dehiscence. In the rabbit model, intravitreal injection resulted in histologically confirmed PVD (eg, bare ILM) in all eyes at the two highest doses following 30-minute incubations; however, eyes exposed to the highest dose displayed subtle alterations in inner retinal architecture, parapapillary retinal hemorrhages, and ERG depression. To date, no follow-up investigations have been conducted.

Plasmin

Undoubtedly the most widely studied vitreolytic agent, plasmin is a serine protease with a critical role in fibrinolysis. In addition to fibrin, plasmin has been shown to directly degrade other ECM components including laminin and fibronectin, which have a postulated role in vitreoretinal adhesion. Plasmin may also indirectly generate increased levels of other nonspecific proteases such as matrix metalloproteinases and elastase, capable of cleaving further ECM structures. These downstream activities may enhance the primary action of plasmin – weakening of vitreoretinal insertion – or may allow for a limited degree of liquefaction. Initial studies of plasmin (1 U) with and without adjunctive vitrectomy or intraocular gas injection in a rabbit model indicated that such adjunctive procedures were necessary to achieve clean vitreoretinal separation. Similar results were obtained in human cadaver eyes using a plasmin-assisted vitrectomy model in which the addition of 1 U of plasmin was found to eliminate the cortical vitreous remnants noted on the ILM in untreated, vitrectomized eyes. Surprisingly, in follow-up studies by the same group in both enucleated pig and human eyes, short incubations (30–60 minutes) with similar doses of plasmin (1–3 U) also resulted in a bare ILM without the use of adjunctive techniques. Further in-vivo studies in rabbits, however, indicated that the previous results in cadaver eyes may have been related to specific properties of post-mortem eyes, as very low rates of complete PVD were found following prolonged exposure (1 week) to 1 U of plasmin. Better rates of complete PVD were achieved with higher doses (4 U). Several studies were able to demonstrate a correlation between both plasmin concentration and exposure time and...
the resultant extent of vitreoretinal separation. The safety profile of intravitreal plasmin in these pre-clinical trials was excellent. Excepting a consistent finding of transient vitreous haze, there were no reported toxicities despite thorough histologic examination with light and EM at doses up to 4 U and with exposure times ranging from 30 minutes to 1 week. No functional toxicity was detected by ERG in three studies, while a fourth found only transient depression of b-wave amplitudes.

As plasmin is exceedingly unstable owing to rapid inactivation via autolysis and binding to α2-antiplasmin, clinical application typically requires activation of its proenzyme, plasminogen, with plasminogen activators immediately prior to use. Application in human trials is further complicated by the lack of an approved, commercially available plasminogen. In place of a commercial alternative, investigators have relied on the time-consuming and expensive process of autologous plasmin enzyme (APE) generation via harvesting a patient’s own plasma-derived plasminogen and purifying it via affinity chromatography. Numerous human pilot studies used this technique to examine outcomes of plasmin-assisted vitrectomy, with doses ranging from 0.03 U up to 2 U, in a variety of VMA-related disorders. Because of the exceptionally strong vitreoretinal adhesion found in pediatric patients, several groups examined the use of APE in the surgical treatment of pediatric traumatic macular holes, stage 5 retinopathy of prematurity, and complicated X-linked retinoschisis; all reported improved anatomic outcomes compared with previously published studies. Other investigators employed plasmin-assisted vitrectomy to treat full-thickness macular holes in patients without pre-existing PVD and found high rates of spontaneous PVD intraoperatively, which reduced overall surgical time. The application of APE prior to vitrectomy resulted in nonsignificant increases in spontaneous PVD and ease of PVD induction in eyes with tractional DME and complicated PDR. One comparative study reported significantly higher visual acuities at 1 year follow-up in patients with DME treated with APE compared with those not receiving such treatment. More recently, a small prospective study found that intravitreal APE without vitrectomy improved central macular thickness and visual acuity in eyes with macular edema complicating branch RVO. Of note, many groups reported varying degrees of vitreous liquefaction following APE administration, although several others either did not comment or noted the lack of liquefaction. In this collection of pilot studies, no investigator reported a clear enzyme-related complication.

Plasminogen activators (tPA and urokinase [UK])

Potent fibrinolytic agents originally approved for a variety of nonophthalmologic vascular disorders including stroke, symptomatic coronary artery, and peripheral vascular occlusive disease, intraocular plasminogen activators have proven to be of modest utility in the treatment of several ophthalmologic conditions including post-surgical fibrin formation, submacular hemorrhage, and acute RVO. As serine proteases capable of activating plasminogen, both tPA and UK exert their effects indirectly through plasmin. Several groups turned to plasminogen activators as potential vitreolytic agents in lieu of plasmin based on: (1) the ease of access to a US Food and Drug Administration-approved commercially available formulation, (2) the safety of a recombinant molecule compared with blood derivatives in terms of microbial contamination, and (3) the established intraocular safety record based on its use for other indications. The challenge in working with plasminogen activators, however, lies in the need for clinically sufficient quantities of intraocular plasminogen, which outside the setting of pathologic blood–retinal barrier breakdown (ie, intraocular inflammation, hemorrhage, PDR), can typically only be achieved via iatrogenic blood–retinal barrier breakdown (ie, cryopexy) or exogenous administration. In a rabbit model, cryopexy followed by tPA and limited vitrectomy (static core vitrectomy only) induced PVD in all treated eyes, whereas no PVD was noted in eyes not receiving either cryopexy or tPA injection. Two later in-vivo rabbit studies examined the efficacy of UK plus exogenous plasminogen with differing results. Complete PVD was noted in all eyes at the two highest nontoxic doses of UK plus purified human plasminogen, but only occurred with the addition of intraocular sulfur hexafluoride following UK plus recombinant plasminogen in a later study. In human pilot studies, tPA-assisted vitrectomy in patients with complicated PDR was not associated with spontaneous PVD induction (assessed intraoperatively) nor with any significant improvement in postoperative functional outcomes. However, a subsequent report of tPA injection alone in patients with RVO-associated macular edema revealed post-treatment PVD in a majority of patients that correlated with improved functional and
anatomic outcomes. Overall, plasminogen activators, much like plasmin, have a promising efficacy and safety record, but their therapeutic potential will continue to be limited by the need for adequate concentrations of intracellular plasminogen substrate. Assuring sufficient quantities of plasminogen, either through exogenous administration or blood–retinal barrier breakdown, inevitably leads to imprecise dosing.

Microplasmin

Another agent initially developed for systemic administration in the treatment of cerebral thromboembolic disease, microplasmin is a recombinant molecule, highly expressed in the *Pichia pastoris* yeast expression system, consisting solely of the catalytic domain of human plasmin. It has several advantages over plasmin: (1) it is commercially available, allowing investigators to avoid the time-intensive and expensive production of APE; (2) it is generated by recombinant techniques, assuring its sterility and avoiding the risk of microbial contamination; (3) it is much smaller than plasmin (22 versus 88 kDa), which theoretically would allow for greater penetration of epiretinal tissues; and (4) it is inherently more stable than plasmin and can be stored in citrate buffer prior to use. It is thus unsurprising – given the greater safety, ease of administration, and dosing accuracy – that investigators increasingly turned to microplasmin for the treatment of VMA-related pathologies in favor of either plasmin or plasminogen activators. The initial pre-clinical studies revealed achievement of complete PVD (eg, bare ILM) at doses ranging from 62.5–125.0 µg (equivalent to 1–2 U of plasmin) in enucleated human eyes with or without adjunctive intraocular gas. In-vivo studies similarly exhibited complete PVD following 7–21 day intravitreal microplasmin exposure with doses differing based on species; cat eyes achieved PVD at doses of 14.5–25.0 µg, while two separate studies in rabbits reported consistent PVD at doses of 125–250 µg. No histologic toxicity or functional toxicity was noted excepting persistent a- and b-wave depression on ERG testing in the 250 µg group only. A later study in enucleated pig eyes utilized a dose-range 62.5–400 µg incubated for 1 or 2 hours) and exposure time-escalation (range 15–120 minutes after 125 µg administration) design. Their results demonstrated both time- and dose-dependent PVD development with a minimal effective dose of 125 µg and a minimal effective incubation period of 60 minutes with 125 µg dose. These values may have been somewhat inflated by the use of room temperature incubations. Although no disruption of cellular anatomy was noted in any experimental eye, serous-like retinal elevations were detected in 25% of eyes exposed to 400 µg for 120 minutes and scattered dendritic-like cells were found on the ILM in eyes receiving doses of 125 µg or higher for 120 minutes, with a greater number of cells in eyes administered higher doses.

Based on the promising anatomic and safety profile reported in these pre-clinical studies, a series of clinical trials was undertaken collectively entitled the Microplasmin Intravitreal Injections (MIVI) trials. MIVI-I was an uncontrolled Phase I/IIa clinical trial designed to assess safety and preliminary efficacy at various doses (25, 50, 75, and 125 µg for 24 hours) and exposures (2 hours, 24 hours, or 7 days following 25 µg administration) of microplasmin in enzyme-assisted vitrectomy for the treatment of VMA-related pathologies including tractional DME, VMT, and full-thickness macular holes. The incidence of spontaneous PVD as well as the ease of PVD induction intraoperatively were found to be both time- and dose-dependent, although no more than 50% of eyes in any one cohort developed spontaneous PVD. Of note, the three eyes in the highest dose cohort were noted to have vitreoschisis intraoperatively, and thus were incorrectly classified as spontaneous PVDs by ultrasound. Aside from a single retinal detachment noted shortly following microplasmin administration, there were no safety concerns ascribed to the study drug. MIVI-Ilt (traction) was a follow-up Phase II prospective sham-controlled trial examining the efficacy of microplasmin alone for the treatment of VMT and early macular holes. In this trial, patients were divided into four cohorts and randomized 4:1 to microplasmin at doses of 75, 125, 175, and repeatable 125 µg doses or sham injection and followed with serial OCT and ultrasound exams. A significantly higher incidence of PVD was noted in the 125 µg cohort as well as the pooled (all doses) microplasmin cohort at 90 days, but not at the remaining time points (14, 28, and 180 days). At 28 days, nonsurgical release of VMA was achieved in 8%, 25%, 44%, and 27% of patients in the sham, 75, 125, and 175 µg cohorts, respectively, with no significant difference observed in the overall analysis or in pairwise comparisons. A larger multicenter Phase IIb prospective placebo-controlled trial, MIVI-III, was subsequently designed to evaluate three doses of microplasmin (25, 75, and 125 µg) compared with placebo administered 7 days prior to vitrectomy for the treatment of a variety of VMA-related disorders. No significant pairwise differences were found in terms of spontaneous PVD induction, but there was significantly greater progression of PVD...
from the date of microplasmin administration until surgery in the 125 µg cohort compared with placebo. Within the 125 µg cohort, there were also a significantly greater proportion of patients in the total cohort as well as within the subset of patients with macular holes who achieved resolution of their condition without the need for vitrectomy versus placebo. Two additional MIVI trials were conducted, but results have yet to be formally published. MIVI-II (TG-MV-002) is a Phase II sham-controlled non-vitreotomy study in patients with tractional DME that completed data collection in March 2010. MIVI-Trust (Traction Release without Surgical Treatment) (TM-MV-006, TM-MV-007) is a Phase III multicenter, randomized, placebo-controlled trial evaluating 125 µg of microplasmin alone for the treatment of focal VMA associated with subjective visual dysfunction, a concept the study designers have labeled “symptomatic VMA,” that completed data collection in July 2010. The preliminary results of this latter trial were reported at the 2011 ARVO (Association for Research in Vision and Ophthalmology) meeting and indicated a statistically significant improvement in the rate of pharmacological resolution of symptomatic VMA in the microplasmin group compared with placebo. Formal publication of results from both of these studies should be forthcoming in the near future.

**RGD peptides**

Widely expressed cell surface receptors, integrins, play a critical role in cellular-ECM adhesion and signaling. Binding to integrins is mediated through a specific binding motif – defined by the amino acid sequence arginine-glycine-aspartate (RGD) – present in a vast array of ECM components including laminin, fibronectin, and certain collagens. Synthetic RGD peptides are known to compete for integrin binding sites, which results in disruption of integrin-ECM interaction and subsequent loosening of attachments. As immunolocalization studies have identified integrins on the surface of the ILM, there has been considerable speculation regarding a possible role of synthetic RGD peptides in disrupting vitreoretinal adhesion, and by extension, a potential utility in vitreolysis. In a rabbit model, 24-hour incubation of intravitreal RGD peptides followed by limited vitrectomy – consisting of 30-second core vitrectomy with attempted PVD induction at low aspiration (≤30 mmHg) – resulted in a significantly greater extent of PVD in treated eyes compared with controls; however, only a single treated eye achieved complete PVD. Aside from focal retinal edema noted in half of the treated eyes, no toxicity was detected on clinical examination, EM analysis, or TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) apoptosis assay. Despite the modest success of this initial study, no further studies have been published.

**Vitreosolve®**

Vitreosolve® (Vitreoretal Technologies Inc, Irvine, CA) is a proprietary nonenzymatic, urea-based molecule currently undergoing Phase II/III testing (PVD-301, PVD-302) in patients with non-proliferative diabetic retinopathy without pre-existing PVD. Given the proprietary nature of the agent, there is little information regarding its structure or mechanism. Preliminary results from an earlier, unpublished study demonstrated PVD induction in 45% of patients following a single 12 mg injection with the proportion rising to 75% following a second injection 30 days later. As Phase II/III trials are currently enrolling patients, final results may be pending for some time.

**Conclusion**

Medical therapy of VMA-related disorders is an exciting and promising area of investigation but currently remains an incompletely realized technology. To facilitate the identification of new agents and maximize the therapeutic potential of current vitreolytics, additional efforts are needed to expand present knowledge of vitreous molecular structure and physiology. Future work on existing agents will undoubtedly draw on the studies reviewed above, though care must be taken in evaluating this body of literature. Two characteristics of previous study design warrant further discussion: PVD definition and clinical model. The modality used to assess for the presence of PVD varies significantly between studies – ranging from clinical examination to ultrasonography to EM – thus complicating inter-study comparison. Moreover, the definition of complete PVD differed significantly and was often related to the assessment modality employed; complete PVD by microscopy typically signified the absence of collagen fibrils on the small specimen of ILM examined, while OCT and ultrasound looked more macroscopically – though perhaps less sensitively – at the vitreoretinal interface. The considerable variability in choice of clinical models also impacts study outcomes. Physiologic PVD is not known to occur in either rabbit or pig eyes – indicating a distinctly different vitreous physiology – and differences in ILM thickness might exaggerate perceived toxicities in certain models. Additionally, use of cadaver models may be confounded by differences in temperature, pH, solubility parameters, and electrolyte
concentrations, which vary depending on the duration of the post-mortem period.160

Study design issues notwithstanding, many of the agents examined to date have shown the capacity to produce significant degrees of vitreous liquefaction or weakening of vitreoretinal adhesion. Unfortunately, these changes are rarely induced concurrently or in the appropriate proportions to induce a safe and reliable PVD. Agents acting either solely through liquefaction (liquefactants such as hyaluronidase and collagenase) or vitreoretinal interface disruption (interfactants such as dispase or RGD peptides) are non-physiologic and have the potential to worsen existing tractional pathology. Plasmin-based agents have shown some ability to concurrently liquefy vitreous and weaken vitreoretinal adhesion; however, the presence of liquefaction is inconsistent and its extent is quite variable.127,131,161 Moreover, some investigators suggest that plasmin/microplasmin-associated liquefaction is actually due to drug-related inflammation and that this change occurs several hours after plasmin exerts its effect on the vitreoretinal interface.165 Such temporal separation of the two components of PVD induction may ultimately reduce efficacy. This combination of factors likely accounts for the surprisingly low rates of spontaneous PVD noted in human trials of plasmin and microplasmin, which were routinely less than 50%.69,77,134,152,153 As no single agent currently appears sufficient for routine PVD production, the future of pharmacologic vitreolysis will likely involve the simultaneous administration of different agents with distinct roles in PVD production.51,90 Two in vivo pre-clinical studies, one in rabbits162 and the second in diabetic rats,162 have utilized this approach with excellent results. In these studies, 80%–100% of eyes treated with a combination of hyaluronidase and plasmin/microplasmin achieved spontaneous PVD without adjunctive procedure compared with much lower rates in eyes treated with the individual agents alone (0%–12.5%). Future studies could explore the use of different doses and combinations of existing agents and could permit the application of agents previously found to be associated with significant toxicity as combination therapy may allow the use of lower doses. Other promising concepts deserving of further exploration include the use of nonenzymatic agents, which offer the potential for vitreolysis without collateral damage to adjacent ECM structures, and the identification of particular agents for specific clinical indications.

Disclosure
The authors report no conflicts of interest in this work.

References


